Ixo et al. in €7.3m round for Antabio

The series-A round included investments from Ixo, Irdi Soridec Gestion, Galia Gestion and the company's previous investors.

The fresh funding has been earmarked to advance Antabio's programmes into clinical studies, accelerating the development of the company's attempt to treat infections caused by pathogens.

Antabio was previously financed through a number of non-dilutive grants.

Company
Antabio is a French biopharmaceutical company developing antibacterial treatments, aiming to fill a gap in the treatment of drug-resistant infections.

Advisers
Equity – Chammas et Marcheteau, Antonin Cubertafond, Romain Penloup (legal).
Company – McDermott Will & Emery, Anthony Paronneau, Laetitia De Dinechin, Chloé Huertas (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Venture
• iXO Private Equity
• France